CSTL Castle Biosciences

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 employees.

"Winning a fourth Top Workplaces USA Award is a testament to our exceptional Castle team and people-first culture," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We are committed to fostering an environment where employees feel valued, supported and empowered to drive innovation, and this recognition reflects their passion and dedication to making a meaningful impact on patient care."

More than 42,000 organizations were invited to participate in the Top Workplaces USA survey. Winners of the Top Workplaces USA list were chosen solely on employee feedback gathered through a third-party administered by Energage. Results were calculated by comparing the survey’s research-based statements, including 15 culture drivers that are indicative of high performance against industry benchmarks. Castle’s survey participation rate of 95% and employee engagement score of 85% were both above the benchmark averages of 56% and 74%, respectively, for other similar healthcare companies participating in the Top Workplaces USA program.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be proud of. In today's market, leaders must ensure they’re allowing employees to have a voice and be heard. That's paramount. Top Workplaces do this, and it pays dividends.”

The comprehensive list of 2025 Top Workplaces USA can be found on and .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit  and connect with us on , ,  and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to worktogether.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 19 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall

Source: Castle Biosciences Inc.



EN
07/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences Reports Second Quarter 2025 Results

Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and...

 PRESS RELEASE

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Gro...

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at . A replay of the webcas...

 PRESS RELEASE

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a ...

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold...

 PRESS RELEASE

FDA Grants Breakthrough Device Designation to Castle Biosciences’ Deci...

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). DecisionDx-Melanoma is a gene expression profile (GEP) test that provides comprehensive, personalized results to guide risk-aligned management decisions for patients diagnosed with s...

 PRESS RELEASE

Castle Biosciences Honored with Multiple Top Workplaces Awards Recogni...

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces aw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch